455 related articles for article (PubMed ID: 25724706)
21. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening.
van Roon AH; Goede SL; van Ballegooijen M; van Vuuren AJ; Looman CW; Biermann K; Reijerink JC; Mannetje H'; van der Togt AC; Habbema JD; van Leerdam ME; Kuipers EJ
Gut; 2013 Mar; 62(3):409-15. PubMed ID: 22387523
[TBL] [Abstract][Full Text] [Related]
22. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
[TBL] [Abstract][Full Text] [Related]
23. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
24. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
[TBL] [Abstract][Full Text] [Related]
25. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
Quintero E
Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
[TBL] [Abstract][Full Text] [Related]
26. Colorectal cancer in a second round after a negative faecal immunochemical test.
Bujanda L; Sarasqueta C; Castells A; Pellisé M; Cubiella J; Gil I; Cosme A; Arana-Arri E; Mar I; Idigoras I; Portillo I;
Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):813-8. PubMed ID: 25856688
[TBL] [Abstract][Full Text] [Related]
27. Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.
de Klerk CM; Wieten E; Lansdorp-Vogelaar I; Bossuyt PM; Spaander MC; Dekker E
Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):111-118. PubMed ID: 30497962
[TBL] [Abstract][Full Text] [Related]
28. Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial.
van Roon AH; Hol L; van Vuuren AJ; Francke J; Ouwendijk M; Heijens A; Nagtzaam N; Reijerink JC; van der Togt AC; van Ballegooijen M; Kuipers EJ; van Leerdam ME
Am J Gastroenterol; 2012 Jan; 107(1):99-107. PubMed ID: 22108450
[TBL] [Abstract][Full Text] [Related]
29. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.
Raginel T; Puvinel J; Ferrand O; Bouvier V; Levillain R; Ruiz A; Lantieri O; Launoy G; Guittet L
Gastroenterology; 2013 May; 144(5):918-25. PubMed ID: 23376426
[TBL] [Abstract][Full Text] [Related]
30. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504
[TBL] [Abstract][Full Text] [Related]
31. The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients.
Cubiella J; Digby J; Rodríguez-Alonso L; Vega P; Salve M; Díaz-Ondina M; Strachan JA; Mowat C; McDonald PJ; Carey FA; Godber IM; Younes HB; Rodriguez-Moranta F; Quintero E; Álvarez-Sánchez V; Fernández-Bañares F; Boadas J; Campo R; Bujanda L; Garayoa A; Ferrandez Á; Piñol V; Rodríguez-Alcalde D; Guardiola J; Steele RJ; Fraser CG;
Int J Cancer; 2017 May; 140(10):2201-2211. PubMed ID: 28187494
[TBL] [Abstract][Full Text] [Related]
32. Demand for Colonoscopy in Colorectal Cancer Screening Using a Quantitative Fecal Immunochemical Test and Age/Sex-Specific Thresholds for Test Positivity.
Chen SL; Hsu CY; Yen AM; Young GP; Chiu SY; Fann JC; Lee YC; Chiu HM; Chiou ST; Chen HH
Cancer Epidemiol Biomarkers Prev; 2018 Jun; 27(6):704-709. PubMed ID: 29593012
[No Abstract] [Full Text] [Related]
33. A quantitative immunochemical fecal occult blood test for colorectal neoplasia.
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Leshno M; Niv Y
Ann Intern Med; 2007 Feb; 146(4):244-55. PubMed ID: 17310048
[TBL] [Abstract][Full Text] [Related]
34. Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study.
Liles EG; Perrin N; Rosales AG; Smith DH; Feldstein AC; Mosen DM; Levin TR
BMC Cancer; 2018 May; 18(1):509. PubMed ID: 29720130
[TBL] [Abstract][Full Text] [Related]
35. Direct Comparison of Diagnostic Performance of 9 Quantitative Fecal Immunochemical Tests for Colorectal Cancer Screening.
Gies A; Cuk K; Schrotz-King P; Brenner H
Gastroenterology; 2018 Jan; 154(1):93-104. PubMed ID: 28958859
[TBL] [Abstract][Full Text] [Related]
36. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
[TBL] [Abstract][Full Text] [Related]
37. Is It Necessary to Repeat Fecal Occult Blood Tests with Borderline Results for Colorectal Cancer Screening?
Lee E; Lee Y
Ann Lab Med; 2018 Jan; 38(1):51-53. PubMed ID: 29071819
[TBL] [Abstract][Full Text] [Related]
38. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
[TBL] [Abstract][Full Text] [Related]
39. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
[TBL] [Abstract][Full Text] [Related]
40. Does Low Threshold Value Use Improve Proximal Neoplasia Detection by Fecal Immunochemical Test?
Kim NH; Yang HJ; Park SK; Park JH; Park DI; Sohn CI; Choi K; Jung YS
Dig Dis Sci; 2016 Sep; 61(9):2685-93. PubMed ID: 27107865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
